Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay
about
Quantitation of human seroresponsiveness to Merkel cell polyomavirusCharacterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United StatesHuman complement receptor type 1/CD35 is an Epstein-Barr Virus receptorExtraordinary antigenicity of the human Ro52 autoantigen.Progress, prospects, and problems in Epstein-Barr virus vaccine development.Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challengeAntibody evasion by a gammaherpesvirus O-glycan shieldA flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurateLuciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases.Epstein-barr virus vaccines.Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell DysfunctionAntibody-profiling technologies for studying humoral responses to infectious agents.LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV.Epstein-Barr virus infection-induced inflammasome activation in human monocytes.Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteKinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.EBV-positive human sera contain antibodies against the EBV BMRF-2 protein.Development of an enzyme-linked immunosorbent spot assay to measure serum-neutralizing antibodies against coxsackievirus B3.Epstein-Barr virus: novel patented therapeutics.Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious MononucleosisA chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in miceTherapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses.Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
P2860
Q21559417-FD88E773-9790-4451-A237-BDB04DDE3FCAQ24617384-CD6C5ADD-58BD-4185-974C-EE870FAEBB14Q24632150-8C5418F2-1F2B-4959-A1A5-C945ACEECB0FQ33793461-50EF2113-47C8-4653-8B5B-A223D94D34D8Q33812640-E456651D-2222-4AAD-8A87-9B74D8FCFDF1Q34058118-D8B641BD-2B19-4FBA-B886-80C03949DBC5Q34082672-17A716B6-13F2-498B-9BA6-91401874DA71Q34242499-1B96CA6C-842E-46D2-B5A2-6317641D1552Q35013894-10CCB494-928F-4CAC-9EC5-BAE78167A118Q35053650-D7521958-004F-46EF-983B-E8AEBAFE88A5Q35913905-ADB8A382-E699-4EE5-9716-8402FFDD5720Q36160093-D48AC14D-6E71-428D-A1E6-785FAA96C8F3Q36196860-A99BFF36-042E-4663-9384-904C2464F2A8Q36332077-391C7CC4-20BF-476B-B797-71EFDFA2889AQ36590540-0728D085-F2BC-4310-A46B-D7589014AEC3Q36764365-8F401D29-196B-4A69-9273-336570DD2AD4Q37086039-BF1A3761-6DD9-4C87-AD15-6C0ACB02CCC5Q37100066-1E60A1A3-8317-4222-A2CA-A61CAB51B037Q37408295-E18D23A2-AACD-4BB7-B80F-8D4005C4EF91Q37643336-E704D37C-16F1-4E69-AC6A-543F0EB0E960Q37729167-C119CDF2-9AC2-475C-B60B-9050AD07A322Q37745980-C701274E-AA53-41DF-9039-00928C97329DQ38735147-C0172BBB-3BFA-4B25-86D9-794CDEFE6DE4Q38885776-A549A0E3-84D6-437D-BE6C-4C1DCEE59DEEQ40994858-A3AEF315-F361-406A-8315-601EB1591BD6Q41557807-F13941C0-FBF9-473D-8112-17D11FB783D6Q52317335-EAEE4769-88F1-4435-B0B6-9F3322985333Q54939538-14DDFD79-4A4C-4510-8141-6A35D45D2B5E
P2860
Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Human antibody titers to Epste ...... based EBV neutralization assay
@ast
Human antibody titers to Epste ...... based EBV neutralization assay
@en
Human antibody titers to Epstein-Barr Virus
@nl
type
label
Human antibody titers to Epste ...... based EBV neutralization assay
@ast
Human antibody titers to Epste ...... based EBV neutralization assay
@en
Human antibody titers to Epstein-Barr Virus
@nl
prefLabel
Human antibody titers to Epste ...... based EBV neutralization assay
@ast
Human antibody titers to Epste ...... based EBV neutralization assay
@en
Human antibody titers to Epstein-Barr Virus
@nl
P2093
P2860
P1433
P1476
Human antibody titers to Epste ...... based EBV neutralization assay
@en
P2093
Barbara Savoldo
Jeffrey I Cohen
Junji Sashihara
Peter D Burbelo
P2860
P304
P356
10.1016/J.VIROL.2009.06.013
P407
P577
2009-07-07T00:00:00Z